For the quarter ended June 2024, Labcorp (LH) reported revenue of $3.22 billion, up 6.2% over the same period last year. EPS came in at $3.94, compared to $3.42 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $3.2 billion, representing a surprise of +0.78%. The company delivered an EPS surprise of +4.23%, with the consensus EPS estimate being $3.78. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectati ...

Labcorp (LH) came out with quarterly earnings of $3.94 per share, beating the Zacks Consensus Estimate of $3.78 per share. This compares to earnings of $3.42 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 4.23%. A quarter ago, it was expected that this medical laboratory operator would post earnings of $3.46 per share when it actually produced earnings of $3.68, delivering a surprise of 6.36%. Over the last four quarters, the ...

Updates Full-Year Guidance Results from Continuing Operations for second quarter 2024 versus last year: Revenue: $3.22 billion versus $3.03 billion Diluted EPS: $2.43 versus $1.74 Adjusted EPS: $3.94 versus $3.42 Free Cash Flow: $432.9 million versus $58.2 million Updated Full-Year 2024 Guidance: Revenue range of 6.4% to 7.5%, includes Invitae impact of ~1.0% Adjusted EPS range of $14.30 to $14.90, includes Invitae dilution of ~$0.40 Free Cash Flow of $0.85 billion to $1.00 billion, includes Invitae cash us ...

BURLINGTON, N.C., and FREMONT, Calif., July 29, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration with Ultima Genomics to utilize its UG 100TM sequencing solution and ppmSeqTM technology to explore new whole genome sequencing (WGS) clinical applications, including molecular residual disease (MRD) in patients with early-stage solid tumor cancers. Labcorp recently introduced Labcorp® Plasma Detect™, the first ...

Laboratory Corporation of America Holdings (LH) , or Labcorp, is slated to report second-quarter 2024 results on Aug 1 before market open. The Zacks Consensus Estimate for Labcorp's second-quarter 2024 revenues is pegged at $3.20 billion. This suggests a 5.4% rise from the year-ago reported figure. Estimates for Labcorp's Q2 earnings have remained unchanged at $3.78 per share in the past 30 days. In the second quarter of 2024, both Diagnostic Laboratories (Dx) and Biopharma Laboratory Services ("BLS") segme ...

BURLINGTON, N.C., July 1, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the second quarter of 2024 before the market opens on Thursday, August 1, 2024. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast ...

Core Insights - Labcorp has launched Labcorp Global Trial Connect, a suite of central laboratory solutions aimed at enhancing the efficiency of clinical trials at investigator sites [1][2]. Group 1: Product Launch and Features - Labcorp Global Trial Connect is designed to simplify the investigator workflow, improve patient experience, and enable biopharma sponsors to expedite the market introduction of therapies [2]. - The suite includes site enablement resources to identify new study opportunities, enhance patient access and recruitment, and improve diversity in clinical trials [2]. - Supply readiness support is provided to increase study startup efficiencies, reduce trial delays, and minimize supply and kit waste [2]. - The platform facilitates site workflows by integrating sample collection and tracking data, offering visibility and actionable analytics to both sites and sponsors, and reducing errors and data revisions through eRequisition functionality [2][3]. - Study management and investigator support are available to accelerate study startup and maintain momentum with 24/7 site support and on-demand tools and training [2]. Group 2: Company Overview - Labcorp is a global leader in laboratory services, assisting healthcare professionals, pharmaceutical companies, and researchers in making informed decisions [4]. - The company employs over 67,000 individuals and operates in approximately 100 countries, supporting 84% of new drugs and therapeutic products approved by the FDA in 2023 [4]. - Labcorp has conducted more than 600 million tests for patients worldwide, showcasing its extensive capabilities in diagnostics and drug development [4].

Labcorp® Tissue Complete, a comprehensive genomic profiling service, now available in Geneva and Shanghai to support global clinical trials Company expands leadership in liquid biopsy comprehensive genomic profiling for solid tumors with the integration of OmniSeq® INSIGHT circulating tumor DNA BURLINGTON, N.C., June 3, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced new strategic service offerings within its precision oncology po ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style S ...

Laboratory Corporation of America Holdings or Labcorp (LH) recently introduced a screening test for preeclampsia in the first trimester, which will be done between weeks 11 and 14 of pregnancy to estimate the risk of preeclampsia before 34 weeks of pregnancy. This is the only test of its kind accessible in the United States and applicable to all expectant mothers, even those with first-time pregnancies or those at low to average risk of preeclampsia. With the latest launch, LK is now the only laboratory tha ...